PPBT

Purple Biotech Ltd ADR

2.19

Sep 02 • 7:44 AM ET +0.53 (31.93%)

Healthcare Biotechnology Israel Nano NASD

Today, 7:35 AMPurple Biotech receives USPTO Notice of Allowance for patent on tri-specific CAPTN-3 modular antibody platform

Peers: APRE GOVX KAPA BCDA BIVI CVM KPRX LNAI NEUP CALC

Scroll to Statements

Index	-
Market Cap	3.55M
Enterprise Value	-2.48M
Income	-24.64M
Sales	0.00M
Book/sh	7.58
Cash/sh	3.77
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Nov 20, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.29
P/C	0.58
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.70
Current Ratio	3.70
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-28.06
EPS next Y	-1.01
EPS next Q	-2.88
EPS this Y	89.57%
EPS next Y	82.37%
EPS next 5Y	78.99%
EPS past 3/5Y	38.10% 29.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	-151.47%
Sales Y/Y TTM	-
EPS Q/Q	110.06%
Sales Q/Q	-
Earnings	Aug 07 BMO
EPS/Sales Surpr.	-217.14% -

Insider Own	0.10%
Insider Trans	0.00%
Inst Own	5.21%
Inst Trans	17.52%
ROA	-101.51%
ROE	-111.29%
ROIC	-200.79%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	36.77%
SMA50	40.58%
SMA200	-48.60%
Trades

Shs Outstand	1.62M
Shs Float	1.62M
Short Float	1.61%
Short Ratio	0.12
Short Interest	0.03M
52W High	19.40 -88.71%
52W Low	1.16 88.79%
Volatility	9.87% 10.49%
ATR (14)	0.19
RSI (14)	77.37
Beta	0.71
Rel Volume	714.09
Avg Volume	222.91K
Volume	7,958,822

Perf Week	26.59%
Perf Month	46.00%
Perf Quarter	-25.76%
Perf Half Y	-56.37%
Perf YTD	-66.69%
Perf Year	-84.58%
Perf 3Y	-99.16%
Perf 5Y	-99.78%
Perf 10Y	-99.96%
Recom	1.00
Target Price	17.00
Prev Close	1.66
Price	2.19
Change %	31.93%

Today 07:30AM	New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies (GlobeNewswire) +31.93%
Aug-07-26 07:00AM	Purple Biotech Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jun-11-26 10:38AM	Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT) (InvestorsHub) -47.97%
07:00AM	Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window (GlobeNewswire)
May-15-26 07:00AM	Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) +6.78%
07:00AM	Loading…
Apr-27-26 07:00AM	Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 (GlobeNewswire)
Apr-23-26 07:00AM	Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform (GlobeNewswire) -8.08%
Mar-25-26 08:00AM	Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform (GlobeNewswire)
Mar-17-26 07:00AM	Purple Biotech Regains Compliance with Nasdaq (GlobeNewswire)
Mar-13-26 08:04AM	Purple Biotech Announces CEO Transition (GlobeNewswire) +6.77%
08:00AM	Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 04:20PM	Purple Biotech Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
Jan-07-26 08:00AM	Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 (GlobeNewswire)
Dec-11-25 07:00AM	Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 (GlobeNewswire)
Dec-04-25 07:00AM	Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress (GlobeNewswire) +8.17%
08:00AM	Loading…
Nov-14-25 08:00AM	Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-29-25 07:33AM	Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform (GlobeNewswire) +81.82%
Oct-20-25 04:00PM	Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Sep-10-25 08:00AM	Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance (GlobeNewswire) -5.28%
Sep-05-25 04:00PM	Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants (GlobeNewswire) -15.38% -9.24%
Sep-04-25 09:15AM	Purple Biotech Announces Pricing of Up To $18 Million Public Offering (GlobeNewswire) -45.07%
07:00AM	Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai (GlobeNewswire)
Sep-03-25 07:00AM	Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 (GlobeNewswire)
Aug-27-25 07:00AM	Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-06-25 07:00AM	Purple Biotech Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-23-25 07:00AM	Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 (GlobeNewswire)
Jun-23-25 07:00AM	Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress (GlobeNewswire)
Jun-17-25 07:00AM	Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer (GlobeNewswire)
Jun-04-25 07:00AM	Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform (GlobeNewswire)
May-21-25 07:10AM	Purple Biotech Reports First Quarter 2025 Financial Results (GlobeNewswire)
07:30AM	Loading…
May-12-25 07:30AM	Purple Biotech Appoints Shai Lankry as Chief Financial Officer (GlobeNewswire)
Apr-30-25 07:00AM	Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups (GlobeNewswire) -5.16%
Apr-28-25 08:28AM	Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers (GlobeNewswire)
Apr-16-25 07:00AM	Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer (GlobeNewswire)
Apr-01-25 07:00AM	Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025 (GlobeNewswire)
Mar-28-25 07:45AM	Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting (GlobeNewswire)
Mar-10-25 08:57AM	Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 07:00AM	Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets (GlobeNewswire)
Feb-18-25 07:00AM	Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial (GlobeNewswire)
Feb-03-25 07:00AM	Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform (GlobeNewswire)
Dec-05-24 07:13AM	Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -16.93%
Dec-03-24 08:23AM	Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -21.79%
Dec-02-24 07:00AM	Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer (GlobeNewswire) +150.37%
Nov-15-24 07:00AM	Purple Biotech Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:13AM	Purple Biotech Unveils Promising Biomarker for Cancer Therapy (TipRanks)
Nov-04-24 07:50AM	Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death (GlobeNewswire)
Oct-25-24 07:20AM	Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.35%
Oct-11-24 07:57AM	Purple Biotech Unveils CAPTN-3 Cancer Therapy (TipRanks)
Oct-10-24 07:30AM	Purple Biotech to Present Data for its Tri-Specific Antibody Platform CAPTN-3 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-18-24 06:30AM	Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 (GlobeNewswire)
Sep-16-24 09:38AM	Upcoming Stock Splits This Week (September 16 to September 20) Stay Invested (TipRanks)
Sep-10-24 07:00AM	Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Aug-30-24 07:00AM	Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +6.30%
Aug-16-24 10:53PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 (InvestorPlace)
08:12AM	Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-25-24 07:35AM	Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule (GlobeNewswire)
Jul-10-24 07:30AM	Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 (GlobeNewswire) +15.31%
Jul-02-24 04:00PM	Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire)
Jul-01-24 09:00AM	Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire) -11.77%
Jun-27-24 07:45AM	Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit (GlobeNewswire) -8.83%
Jun-01-24 08:00AM	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer (GlobeNewswire)
May-21-24 01:52PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024 (InvestorPlace) +6.54%
07:30AM	Purple Biotech Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting (GlobeNewswire)
Mar-28-24 07:00AM	Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 (GlobeNewswire) +9.66%
Mar-14-24 07:30AM	Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology (GlobeNewswire)
Mar-13-24 09:55AM	Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher (Zacks)
Mar-05-24 11:52PM	PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:00AM	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 (GlobeNewswire) -5.91%
Feb-13-24 07:00AM	Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial (GlobeNewswire)
Feb-01-24 07:30AM	Purple Biotech Reaches Recommended Phase 2 Dose for NT219 (GlobeNewswire)
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire) -9.17%
Dec-14-23 06:50AM	Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial (GlobeNewswire)
Nov-21-23 06:50AM	Purple Biotech Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:00AM	Purple Biotech Fortifies NT219 Patent Protection (GlobeNewswire)
Oct-19-23 03:55PM	Purple Biotech Announces Closing of $5 Million Registered Direct Offering (GlobeNewswire) +13.04%
Oct-17-23 08:00AM	Purple Biotech Announces $5 Million Registered Direct Offering (GlobeNewswire)
Oct-06-23 07:50AM	Purple Biotech Reports Potential Biomarker Data Support CM24s Mechanism of Action (GlobeNewswire)
Oct-03-23 07:50AM	Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer (GlobeNewswire) -8.18%
Sep-21-23 08:00AM	Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023 (GlobeNewswire) +8.82%
Aug-22-23 09:29AM	Purple Biotech Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-11-23 08:15AM	Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients (GlobeNewswire) -7.72%
May-16-23 04:00PM	Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:00AM	Purple Biotech Debuts Scientific Advisory Board (GlobeNewswire)
Apr-19-23 08:15AM	Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors (GlobeNewswire)
Apr-18-23 07:00AM	Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-24-23 07:00AM	Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron (GlobeNewswire) -5.11%
Mar-16-23 07:00AM	Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study (GlobeNewswire)
Feb-14-23 07:01AM	Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial (GlobeNewswire) +6.68%
Feb-08-23 07:12AM	Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer (GlobeNewswire) +6.18%
Jan-03-23 07:00AM	Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments (GlobeNewswire)
Nov-15-22 07:00AM	Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis (GlobeNewswire) +5.37%
Nov-10-22 07:00AM	Purple Biotech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-08-22 07:53AM	Purple Biotech Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.63%
Nov-02-22 07:37AM	Purple Biotech Appoints Lior Fhima as Chief Financial Officer (GlobeNewswire)
Aug-04-22 07:30AM	Purple Biotech Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 07:30AM	Purple Biotech Announces Executive Leadership Changes (GlobeNewswire)
May-27-22 07:15AM	Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile (GlobeNewswire) -6.21%

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

M.A.Mr. Gil Efron CPA

M.B.A.Mr. Shai Lankry CPA

Head of Clinical & Regulatory AffairsDr. Michael Schickler Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PPBT

Purple Biotech Ltd ADR

Upgrade your Finviz experience